HRP20100676T1 - Cvrsti farmaceutski pripravak koji sadrzi benzazepine i postupak njegovog dobivanja - Google Patents
Cvrsti farmaceutski pripravak koji sadrzi benzazepine i postupak njegovog dobivanja Download PDFInfo
- Publication number
- HRP20100676T1 HRP20100676T1 HR20100676T HRP20100676T HRP20100676T1 HR P20100676 T1 HRP20100676 T1 HR P20100676T1 HR 20100676 T HR20100676 T HR 20100676T HR P20100676 T HRP20100676 T HR P20100676T HR P20100676 T1 HRP20100676 T1 HR P20100676T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- solid pharmaceutical
- hydroxypropyl cellulose
- weight
- amount
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract 22
- 238000002360 preparation method Methods 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 150000008038 benzoazepines Chemical class 0.000 title 1
- 239000002245 particle Substances 0.000 claims abstract 12
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract 8
- -1 hydroxypropoxyl group Chemical group 0.000 claims abstract 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical compound CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 claims abstract 8
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract 4
- 229920002472 Starch Polymers 0.000 claims abstract 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 4
- 229940069328 povidone Drugs 0.000 claims abstract 4
- 239000011734 sodium Substances 0.000 claims abstract 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract 4
- 239000008107 starch Substances 0.000 claims abstract 4
- 235000019698 starch Nutrition 0.000 claims abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 239000008187 granular material Substances 0.000 claims 4
- 238000005469 granulation Methods 0.000 claims 4
- 230000003179 granulation Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cvrsti farmaceutski pripravak, naznacen time sto sadrzi: (a) 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepin i/ili njegovu sol; (b) hidroksipropilcelulozu koja sadrzi hidroksipropoksilnu skupinu u kolicini od 50 %, tezinski, ili vecoj; i (c) najmanje jedan clan kojeg se bira iz skupine koju cine karboksimetilceluloza, natrij-karboksimetilskrob, umrezeni povidon i nisko supstituirana hidroksipropilceluloza, prosjecnog promjera cestica od 30 do 70 μm, gdje 90 % cestica ima ukupni promjer od 100 do 200 μm. Patent sadrzi jos 16 patentnih zahtjeva.
Claims (17)
1. Čvrsti farmaceutski pripravak, naznačen time što sadrži:
(a) 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepin i/ili njegovu sol;
(b) hidroksipropilcelulozu koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj; i
(c) najmanje jedan član kojeg se bira iz skupine koju čine karboksimetilceluloza, natrij-karboksimetilškrob, umreženi povidon i nisko supstituirana hidroksipropilceluloza, prosječnog promjera čestica od 30 do 70 µm, gdje 90 % čestica ima ukupni promjer od 100 do 200 µm.
2. Čvrsti farmaceutski pripravak, naznačen time što sadrži:
(a) 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepin i/ili njegovu sol;
(b) hidroksipropilcelulozu koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj; i
(c-1) nisko supstituiranu hidroksipropilcelulozu, prosječnog promjera čestica od 30 do 70 µm, gdje 90 % čestica ima ukupni promjer od 100 do 200 µm.
3. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što prosječni promjer čestica nisko supstituirane hidroksipropilceluloze je 45 do 65 µm, gdje 90 % čestica ima ukupni promjer od 100 do 200 µm.
4. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što čvrsti farmaceutski pripravak je u obliku tablete.
5. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što se dobiva postupkom koji se sastoji od:
Koraka 1 dobivanja amorfne smjese iz 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepina i/ili njegove soli i hidroksipropilceluloze koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj;
Koraka 2 miješanja amorfne smjese dobivene u Koraku 1 s nisko supstituiranom hidroksipropilcelulozom, prosječnog promjera čestica od 30 do 70 µm, gdje 90 % čestica ima ukupni promjer od 100 do 200 µm; i
Koraka 3 obrade smjese dobivene u Koraku 2 u čvrsti pripravak.
6. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što ga se proizvodi postupkom koji se dodatno sastoji od, između Koraka 1 i Koraka 2, koraka obrade amorfne smjese dobivene u Koraku 1 u granule postupkom granuliranja.
7. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 5, naznačen time što ga se proizvodi postupkom koji se dodatno sastoji od, između Koraka 2 i Koraka 3, koraka obrade smjese dobivene u Koraku 2 u granule postupkom granuliranja.
8. Postupak proizvodnje čvrstog farmaceutskog pripravka u skladu s patentnim zahtjevom 2, naznačen time što se navedeni postupak sastoji od:
Koraka 1 dobivanja amorfne smjese iz 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepina i/ili njegove soli i hidroksipropilceluloze koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj;
Koraka 2 miješanja amorfne smjese dobivene u Koraku 1 s nisko supstituiranom hidroksipropilcelulozom, prosječnog promjera čestica od 30 do 70 µm, gdje 90 % čestica ima ukupni promjer od 100 do 200 µm; i
Koraka 3 obrade smjese dobivene u Koraku 2 u čvrsti pripravak.
9. Postupak u skladu s patentnim zahtjevom 8, naznačen time što Korak 3 se provodi obradom smjese dobivene u Koraku 2 u tablete.
10. Postupak u skladu s patentnim zahtjevom 8 ili 9, naznačen time što se dodatno sastoji, između Koraka 1 i Koraka 2, od koraka obrade amorfne smjese dobivene u Koraku 1 u granule postupkom granuliranja.
11. Postupak u skladu s patentnim zahtjevom 8 ili 9, naznačen time što se dodatno sastoji, između Koraka 2 i Koraka 3, od koraka obrade smjese dobivene u Koraku 2 u granule postupkom granuliranja.
12. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što sadrži:
(a) 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepin i/ili njegovu sol;
(b) hidroksipropilcelulozu koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj; i
(c-2) karboksimetilcelulozu.
13. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time što udio karboksimetilceluloze je 7 do 15 %, težinski, od ukupne količine čvrstog farmaceutskog pripravka.
14. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što sadrži:
(a) 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepin i/ili njegovu sol;
(b) hidroksipropilcelulozu koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj; i
(c-3) natrij-karboksimetilškrob.
15. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time što udio natrij-karboksimetilškroba je 0,5 do 15 %, težinski, od ukupne količine čvrstog farmaceutskog pripravka.
16. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što sadrži:
(a) 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoil]-2,3,4,5-tetrahidro-1H-benzoazepin i/ili njegovu sol;
(b) hidroksipropilcelulozu koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj; i
(c-4) umreženi povidon.
17. Čvrsti farmaceutski pripravak u skladu s patentnim zahtjevom 16, naznačen time što udio umreženog povidona je 2 do 15 %, težinski, od ukupne količine čvrstog farmaceutskog pripravka.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007163551 | 2007-06-21 | ||
| PCT/JP2008/061686 WO2008156217A2 (en) | 2007-06-21 | 2008-06-20 | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100676T1 true HRP20100676T1 (hr) | 2011-01-31 |
Family
ID=40070798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100676T HRP20100676T1 (hr) | 2007-06-21 | 2010-12-07 | Cvrsti farmaceutski pripravak koji sadrzi benzazepine i postupak njegovog dobivanja |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10905694B2 (hr) |
| EP (1) | EP2167046B1 (hr) |
| JP (1) | JP5289338B2 (hr) |
| KR (1) | KR101526625B1 (hr) |
| CN (3) | CN101686941A (hr) |
| AR (1) | AR067077A1 (hr) |
| AT (1) | ATE489944T1 (hr) |
| AU (1) | AU2008264445B2 (hr) |
| BR (1) | BRPI0813100A2 (hr) |
| CA (1) | CA2689467A1 (hr) |
| CY (1) | CY1111939T1 (hr) |
| DE (1) | DE602008003816D1 (hr) |
| DK (1) | DK2167046T3 (hr) |
| ES (1) | ES2354030T3 (hr) |
| HK (1) | HK1201719A1 (hr) |
| HR (1) | HRP20100676T1 (hr) |
| IL (1) | IL202179A (hr) |
| MX (1) | MX2009014193A (hr) |
| MY (1) | MY147599A (hr) |
| PL (1) | PL2167046T3 (hr) |
| PT (1) | PT2167046E (hr) |
| RU (1) | RU2466717C2 (hr) |
| SI (1) | SI2167046T1 (hr) |
| TW (1) | TWI405574B (hr) |
| WO (1) | WO2008156217A2 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102293734A (zh) * | 2010-06-25 | 2011-12-28 | 江苏恒瑞医药股份有限公司 | 托伐普坦固体分散体及其制备方法 |
| CN102552278A (zh) * | 2010-12-23 | 2012-07-11 | 天津泰普药品科技发展有限公司 | 一种提高难溶性药物托伐普坦溶出度的药物组合物 |
| CN102228423B (zh) * | 2011-06-29 | 2013-03-06 | 重庆市庆余堂制药有限公司 | 托伐普坦口服固体药物组合物及其制备方法 |
| JP6057628B2 (ja) * | 2012-09-06 | 2017-01-11 | クリーンケミカル株式会社 | 人工透析装置のプライミング方法 |
| TWI660748B (zh) | 2013-03-01 | 2019-06-01 | 日商大塚製藥股份有限公司 | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 |
| TW201605488A (zh) | 2013-10-15 | 2016-02-16 | 大塚製藥股份有限公司 | 用以預防及／或治療多囊腎病之藥物 |
| JP6761695B2 (ja) * | 2016-08-16 | 2020-09-30 | 信越化学工業株式会社 | 低置換度ヒドロキシプロピルセルロース及び固形製剤 |
| JP6838446B2 (ja) * | 2017-03-22 | 2021-03-03 | ニプロ株式会社 | トルバプタン製剤およびその製造方法 |
| JP7352175B2 (ja) * | 2019-12-25 | 2023-09-28 | ニプロ株式会社 | トルバプタン製剤 |
| CN111888335A (zh) * | 2020-08-21 | 2020-11-06 | 福安药业集团重庆礼邦药物开发有限公司 | 一种托伐普坦的药物固体制剂及制备方法 |
| US20240366625A1 (en) | 2021-06-02 | 2024-11-07 | Esperion Therapeutics, Inc. | Compositions containing and therapies using bempedoic acid and tolvaptan |
| EP4321154A1 (en) | 2022-08-03 | 2024-02-14 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet of tolvaptan and at least one binder processed with spray granulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2071511A (en) * | 1934-10-01 | 1937-02-23 | Reed & Carnrick | Enteric coating |
| DE122009000062I2 (de) | 1989-10-20 | 2011-01-13 | Otsuka Pharma Co Ltd | Benzoheterozyklische verbindungen |
| TW430561B (en) * | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
| JPH09278656A (ja) | 1996-02-05 | 1997-10-28 | Sankyo Co Ltd | 経口投与用５α−リダクターゼ阻害製剤及びその製造方法 |
| PT965339E (pt) * | 1996-11-15 | 2006-06-30 | Ajinomoto Kk | Composicao de nateglinida em comprimidos |
| JP4210355B2 (ja) * | 1997-07-03 | 2009-01-14 | 大塚製薬株式会社 | 固形製剤組成物 |
| CA2587022A1 (en) * | 1998-05-18 | 1999-11-25 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| EP1054019A1 (en) * | 1999-05-18 | 2000-11-22 | Shin-Etsu Chemical Co., Ltd. | Low-substituted hydroxypropyl cellulose |
| EP1385486A4 (en) * | 2001-04-18 | 2006-05-17 | Nostrum Pharmaceuticals Inc | NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION |
| JP2004026861A (ja) * | 2002-06-21 | 2004-01-29 | Shin Etsu Chem Co Ltd | 濾過性に優れる水溶性セルロースエーテル及びその選定方法 |
| JP4684545B2 (ja) | 2002-09-26 | 2011-05-18 | 大日本住友製薬株式会社 | 溶出性の良好なイソキサゾール誘導体経口製剤 |
| TWI322689B (en) * | 2003-02-24 | 2010-04-01 | Otsuka Pharma Co Ltd | Method for treating severe heart failure and medicament therefor |
| WO2004087109A1 (ja) * | 2003-03-27 | 2004-10-14 | Hisamitsu Pharmaceutical Co., Inc. | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 |
| TW200507882A (en) | 2003-07-17 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Solid formulations |
| US8158146B2 (en) * | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
-
2008
- 2008-06-19 TW TW097122847A patent/TWI405574B/zh active
- 2008-06-20 US US12/665,642 patent/US10905694B2/en active Active
- 2008-06-20 EP EP08777650A patent/EP2167046B1/en active Active
- 2008-06-20 AT AT08777650T patent/ATE489944T1/de active
- 2008-06-20 WO PCT/JP2008/061686 patent/WO2008156217A2/en active Application Filing
- 2008-06-20 BR BRPI0813100-7A2A patent/BRPI0813100A2/pt not_active Application Discontinuation
- 2008-06-20 PT PT08777650T patent/PT2167046E/pt unknown
- 2008-06-20 PL PL08777650T patent/PL2167046T3/pl unknown
- 2008-06-20 DE DE602008003816T patent/DE602008003816D1/de active Active
- 2008-06-20 MX MX2009014193A patent/MX2009014193A/es active IP Right Grant
- 2008-06-20 DK DK08777650.6T patent/DK2167046T3/da active
- 2008-06-20 AU AU2008264445A patent/AU2008264445B2/en active Active
- 2008-06-20 MY MYPI20095067A patent/MY147599A/en unknown
- 2008-06-20 AR ARP080102630A patent/AR067077A1/es not_active Application Discontinuation
- 2008-06-20 CN CN200880021079A patent/CN101686941A/zh active Pending
- 2008-06-20 CN CN2013100344832A patent/CN103463095A/zh active Pending
- 2008-06-20 CA CA002689467A patent/CA2689467A1/en not_active Abandoned
- 2008-06-20 JP JP2009553855A patent/JP5289338B2/ja active Active
- 2008-06-20 KR KR1020107001313A patent/KR101526625B1/ko active IP Right Grant
- 2008-06-20 ES ES08777650T patent/ES2354030T3/es active Active
- 2008-06-20 CN CN201410181750.3A patent/CN103989644A/zh active Pending
- 2008-06-20 RU RU2010101797/15A patent/RU2466717C2/ru active
- 2008-06-20 SI SI200830150T patent/SI2167046T1/sl unknown
-
2009
- 2009-11-17 IL IL202179A patent/IL202179A/en active IP Right Grant
-
2010
- 2010-06-18 HK HK15101484.4A patent/HK1201719A1/xx unknown
- 2010-12-07 HR HR20100676T patent/HRP20100676T1/hr unknown
-
2011
- 2011-02-14 CY CY20111100172T patent/CY1111939T1/el unknown
-
2020
- 2020-11-16 US US17/099,221 patent/US20210069207A1/en not_active Abandoned
- 2020-12-23 US US17/132,852 patent/US20210113582A1/en not_active Abandoned
-
2023
- 2023-06-16 US US18/336,534 patent/US20230321113A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100676T1 (hr) | Cvrsti farmaceutski pripravak koji sadrzi benzazepine i postupak njegovog dobivanja | |
| HRP20161329T1 (hr) | Oralni oblici doziranja koji sadrže likarbazepin acetat | |
| HRP20161262T1 (hr) | Tablete ulipristal acetata | |
| Sekar et al. | Immediate release tablets of telmisartan using superdisintegrant-formulation, evaluation and stability studies | |
| AU2011269506B2 (en) | Tolvaptan solid dispersion and its preparation method | |
| RU2013114411A (ru) | Устойчивая к разрушению лекарственная форма, которая содержит анионный полимер | |
| JP2011241218A5 (hr) | ||
| RU2011112362A (ru) | Твердые препаративные формы оспемифена | |
| JP2007523210A5 (hr) | ||
| BR9912846B1 (pt) | processo para fabricar um tablete de liberação controlada. | |
| ATE329582T1 (de) | Herstellung von tabletten von pharmazeutisch aktiven substanzen mit ungünstigen tablettierungseigenschaften mit einer mikrokristalline zellulose enthaltenden granulierflüssigkeit | |
| CN104337787B (zh) | 含有利伐沙班的药物制剂 | |
| CN103520169A (zh) | 米氮平片及其制备方法 | |
| CN104523638B (zh) | 含有草酸艾司西酞普兰的片剂及其制备方法 | |
| JP2009519313A5 (hr) | ||
| CN102697778A (zh) | 缬沙坦氨氯地平复方固体制剂及其制备方法 | |
| RU2020130411A (ru) | Гранулярная композиция, способ получения гранулярной композиции и способ улучшения свойств растворения для гранулярной композиции | |
| JP2017520619A5 (hr) | ||
| CN102274162A (zh) | 一种含有难溶性药物和亲水凝胶材料的固体组合物及其制备方法 | |
| JP2004522780A5 (hr) | ||
| CN101507716A (zh) | 硝苯地平缓释制剂及其制备方法 | |
| CN101711753A (zh) | 兰索拉唑固体制剂的制备方法 | |
| JP2015229659A (ja) | イブプロフェン含有錠剤およびその製造方法 | |
| JP2007063217A (ja) | プランルカスト水和物含有錠及びその製造方法 | |
| CN103520732B (zh) | 含有两种崩解剂联用的阿折地平制剂及其制备方法 |